An Open-Label Study to Assess Monthly Risperidone Injections (180 mg) Following Switch from Daily Oral Risperidone (6 mg) in Stable Schizophrenic Patients

ConclusionsThe results support the use of 180  mg RBP-7000 in schizophrenic patients stable on 6 mg/day oral risperidone and a second injection site in the upper arm.Trial RegistrationClinicalTrials.gov identifier: NCT03978832.
Source: Clinical Drug Investigation - Category: Drugs & Pharmacology Source Type: research